Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Barclays PLC

Barclays PLC increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 101.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 255,883 shares of the company's stock after buying an additional 128,823 shares during the quarter. Barclays PLC owned about 0.18% of Denali Therapeutics worth $7,454,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of DNLI. Nomura Asset Management Co. Ltd. purchased a new stake in Denali Therapeutics during the 3rd quarter worth $1,894,000. Pier Capital LLC increased its position in shares of Denali Therapeutics by 1.6% during the third quarter. Pier Capital LLC now owns 168,082 shares of the company's stock worth $4,896,000 after acquiring an additional 2,596 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Denali Therapeutics by 9.2% in the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock worth $312,491,000 after acquiring an additional 903,683 shares in the last quarter. Polar Asset Management Partners Inc. boosted its holdings in Denali Therapeutics by 70.5% in the third quarter. Polar Asset Management Partners Inc. now owns 41,100 shares of the company's stock valued at $1,197,000 after purchasing an additional 17,000 shares during the last quarter. Finally, Holocene Advisors LP grew its stake in Denali Therapeutics by 65.0% during the 3rd quarter. Holocene Advisors LP now owns 97,447 shares of the company's stock valued at $2,839,000 after purchasing an additional 38,405 shares in the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Jefferies Financial Group increased their target price on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Raymond James reissued a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Stifel Nicolaus raised shares of Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 price target on the stock in a research report on Monday. HC Wainwright reissued a "buy" rating and issued a $90.00 price objective on shares of Denali Therapeutics in a report on Thursday, November 7th. Finally, Cantor Fitzgerald downgraded Denali Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $40.40.

Denali Therapeutics Trading Up 0.3 %

DNLI traded up $0.06 during trading on Thursday, reaching $21.49. 1,572,375 shares of the company were exchanged, compared to its average volume of 1,055,358. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33. The firm has a 50 day moving average of $26.04 and a 200 day moving average of $24.89. The stock has a market cap of $3.09 billion, a P/E ratio of -7.79 and a beta of 1.35.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the business earned ($0.72) EPS. As a group, analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total transaction of $30,600.00. Following the sale, the director now owns 111,056 shares of the company's stock, valued at $3,331,680. The trade was a 0.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander O. Schuth sold 15,558 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the transaction, the insider now directly owns 178,066 shares of the company's stock, valued at approximately $5,325,954.06. The trade was a 8.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 86,578 shares of company stock valued at $2,474,440 in the last ninety days. Company insiders own 7.90% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.